The Centre for Proteomic & Genomic Research in Cape Town, South Africa, a biology research facility, has signed an agreement with CapitalBio Corp. of Beijing, a biochip and microarray technology developer. The acquisition will provide the former with access to microarray assay platforms, while the latter will form a testing facility for tuberculosis strain typing and drug resistance testing.